Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Common Equity (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Common Equity data on record, last reported at $631.0 million in Q4 2025.

  • For Q4 2025, Common Equity changed N/A year-over-year to $631.0 million; the TTM value through Dec 2025 reached $631.0 million, changed N/A, while the annual FY2025 figure was $631.0 million, N/A changed from the prior year.
  • Common Equity reached $631.0 million in Q4 2025 per RCUS's latest filing, up from $436.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $842.0 million in Q4 2021 and bottomed at $436.0 million in Q3 2025.
  • Average Common Equity over 5 years is $618.7 million, with a median of $604.6 million recorded in 2021.
  • Peak YoY movement for Common Equity: soared 372.7% in 2021, then dropped 29.68% in 2023.
  • A 5-year view of Common Equity shows it stood at $842.0 million in 2021, then decreased by 21.97% to $657.0 million in 2022, then fell by 29.68% to $462.0 million in 2023, then rose by 22.29% to $565.0 million in 2024, then grew by 11.68% to $631.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $631.0 million in Q4 2025, $436.0 million in Q3 2025, and $549.0 million in Q2 2025.